Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ELOX
- Price
- -
- Stock movement up
- +- (0.00%)
- Company name
- Eloxx Pharmaceuticals Inc
- Exchange
- (PINK ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 314.00
- Ent value
- 21.32M
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -100.00%
- 3 year return (CAGR)
- -98.84%
- 5 year return (CAGR)
- -94.67%
- 10 year return (CAGR)
- -81.58%
Last updated: 2024-12-17
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ELOX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 3.14M |
| EPS (TTM) | -7.45 |
| FCF per share (TTM) | -6.55 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -19.29M |
| Net income (TTM) | -20.48M |
| EPS (TTM) | -7.45 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 4.78M |
| Net receivables | 0.00 |
| Total current assets | 5.63M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 413.00K |
| Total assets | 6.04M |
| Accounts payable | 3.13M |
| Short/Current long term debt | 5.76M |
| Total current liabilities | 23.47M |
| Total liabilities | 26.09M |
| Shareholder's equity | -20.05M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -17.99M |
| Capital expenditures (TTM) | 18.00K |
| Free cash flow (TTM) | -18.01M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -338.99% |
| Return on Invested Capital | 143.30% |
| Cash Return on Invested Capital | 126.00% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
No data
Stock price data
| Open | 0.00 |
| Daily high | 0.00 |
| Daily low | 0.00 |
| Daily Volume | 0K |
| 1y analyst estimate | 30.00 |
| Beta | -24.60 |
| EPS (TTM) | -7.45 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| ELOX | S&P500 | |
| Current price drop from All-time high | -100.00% | - |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 6 Dec 2024 | 9 Mar 2009 |
| Avg drop from high | -81.11% | -10.84% |
| Avg time to new high | 628 days | 12 days |
| Max time to new high | 5743 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
314.00
Marketcap category
Small-cap
Description
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
Employees
18
Website
Investor relations
-
SEC filings
CEO
Gregory C. Williams
Country
USA
City
Waltham
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page